The Motley Fool
12 Jul 2026, 19:06 UTC · 2h ago
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
12 Jul 2026, 19:06 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Corcept Therapeutics raised its full-year revenue guidance to between $950 million and $1.05 billion. — Upwardly revised revenue guidance is a primary driver of stock price appreciation and signals commercial growth.
+0.60The FDA approved Corcept's ovarian cancer drug, Lifyorli, more than three months ahead of schedule. — Accelerated regulatory approval for a new product expands the company's addressable market and revenue streams.
+0.50Corcept resubmitted its new drug application for relacorilant as a treatment for Cushing syndrome following a previous FDA rejection. — Resubmission creates a positive catalyst potential, although it carries risk if the FDA rejects it again.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Chief Development Officer William Guyer sold 20,000 shares of Corcept Therapeutics on July 7, 2026. — Insider selling can be viewed negatively, but the impact is muted here as the trade was pre-planned in November 2024.
-0.10Which stocks this story touches
Despite an insider sale, the company received an early FDA approval for Lifyorli and raised its full-year revenue guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
3h ago
